

Company Number: 149066

**Medical Dynamics Teoranta
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025**

Medical Dynamics Teoranta
CONTENTS

	Page
Statement of Financial Position	3
Notes to the Financial Statements	4 - 5

Medical Dynamics Teoranta
STATEMENT OF FINANCIAL POSITION

as at 30 April 2025

	2025	2024
	€	€
Fixed Assets	<u>306,151</u>	<u>320,707</u>
Current assets	422,875	425,123
Prepayments and accrued income	290	281
Creditors: amounts falling due within one year	<u>(78,336)</u>	<u>(50,328)</u>
Net Current Assets	<u>344,829</u>	<u>375,076</u>
Total Assets less Current Liabilities	650,980	695,783
Accruals and deferred income	<u>(64,418)</u>	<u>(63,575)</u>
Net Assets	<u><u>586,562</u></u>	<u><u>632,208</u></u>
Capital and Reserves	<u><u>586,562</u></u>	<u><u>632,208</u></u>

The financial statements have been prepared in accordance with the micro-companies' regime and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime".

We as Directors of Medical Dynamics Teoranta, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014 (as a micro company). The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

Approved by the Directors and authorised for issue on 10 December 2025 and signed on its behalf by:

Andria Moran
Director

Maurice Moran
Director

Medical Dynamics Teoranta

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Medical Dynamics Teoranta is a company limited by shares incorporated in Ireland.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

Turnover

Turnover represents net income from tenants and excludes Value Added Tax.

Dividends

Dividends to the company's equity shareholders (holders of ordinary shares) are recognised as a liability of the company when approved by the company's shareholders.

Consolidation

The company and its other group entities combined meet the size exemption criteria for a group and the company is therefore exempt from the requirement to prepare consolidated financial statements deal by virtue of section 297 of the Companies Act 2014. Consequently these financial statements deal with the results of the company as a single entity.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	12.5% Reducing Balance
----------------------------------	---	------------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Investment properties

Investment property is property held either to earn rental income, or for capital appreciation (including future re-development) or for both, but not for sale in the ordinary course of business.

Investment property is initially measured at cost, which includes the purchase cost and any directly attributable expenditure. Investment property is subsequently valued at its fair value every five years, by professional external valuers. The difference between the fair value of an investment property at the reporting date and its carrying value prior to the valuation is recognised in the Income Statement as a fair value gain or loss. Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in the Income Statement.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Medical Dynamics Teoranta

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Share capital of the company

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Appropriation of Income Statement	2025 €	2024 €
Profit brought forward	632,081	672,724
Profit for the financial year	61,354	72,357
Dividends paid	(107,000)	(113,000)
Profit carried forward	586,435	632,081

4. Related party transactions

Transactions and balances with group company:

	2025 €	2024 €
AIMID Limited		
There is an amount receivable from AIMID Limited of € 1 which owns 60% of the issued share capital of the company (2024 - € 2,124).		
Management charges of € 17,000 are payable to AIMID Limited which owns 60% of the issued share capital of the company (2024 - € 17,000).		
Amount due from AIMID Limited	<u>1</u>	<u>2,124</u>

5. Parent company

The company regards AIMID Limited as its parent company.

6. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

7. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 10 December 2025.